Suvretta Capital Management 13F annual report

Suvretta Capital Management is an investment fund managing more than $2.19 trillion ran by Glenn Shepard. There are currently 87 companies in Mr. Shepard’s portfolio. The largest investments include Biohaven Ltd and Arcellx Inc, together worth $331 billion.

Limited to 30 biggest holdings

$2.19 trillion Assets Under Management (AUM)

As of 7th February 2024, Suvretta Capital Management’s top holding is 4,572,836 shares of Biohaven Ltd currently worth over $196 billion and making up 8.9% of the portfolio value.Relative to the number of outstanding shares of Biohaven Ltd, Suvretta Capital Management owns less than approximately 0.1% of the company.In addition, the fund holds 2,435,974 shares of Arcellx Inc worth $135 billion. The third-largest holding is Royalty Pharma plc worth $109 billion and the next is Ultragenyx Pharmaceutical In worth $102 billion, with 2,126,306 shares owned.

Currently, Suvretta Capital Management's portfolio is worth at least $2.19 trillion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Suvretta Capital Management

The Suvretta Capital Management office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Glenn Shepard serves as the Chief Financial Officer at Suvretta Capital Management.